OUVERTURE

Bruno VAN POTTELSBERGHE Solvay Brussels School



Le rôle de la Propriété Intellectuelle dans les interactions entre Science et Industrie

Quelle perspective européenne?













La propriété intellectuelle dans les relations science-industrie

Strasbourg, IEEPI, 7 April 2022

Prof. Bruno van Pottelsberghe


Solvay Brussels School of Economics and Management, ULB Chairman, Knowledge Transfer Committee, ULB



Historical Perspective



A knowledge transfer success?





Alexander Fleming

- 1928, discovery but not enough funding in St Mary's Hopital
 - Tranfer research to Oxford University : Chain and Florey
 - Funded by the government & Rockfeller Foundation (US)
- 1939: first successful therapeutical experiments
- 1945: Nobel Prize for Fleming, Chain and Florey
- Florey and Chain decided not to apply for a patent! ...
 - Regulation: not allowed
 - Cultural context
 - Disagreement between them



The Penicillin business...





Historical perspectives





LEARNING FROM THE CASE

- Public funding matters, for scientific AND social progress
- The socio-economic return can be ... "anywhere in the world"
- Technology transfer can generate resources, securing local 'impact'
- Academic patenting generates debates
 - Within academic community: "Intellectual weakness"?
 - Within academic and policy makers: "does it block innovation?"
 - Within university administrations: is it break-even?
 - Within government bodies: when subsidized, is it "worth it"?



- Historical perspectives
- Learning from the case





POLICY MAKING, 1980...

1980 USA: The Bayh-Dole Act


Change in ownership of inventions made with federal funding. Before 1980 inventors assigned inventions to the federal government.

Bayh–Dole permits a university to elect to *pursue ownership* of an invention

2010: Betsy de Parry. "I am alive today because of you!"



Birch Bayh




Bob Dole





POLICY MAKING, 1980-2000 IN EU...

Figure 5-35 EPO patents granted to U.S. and non-U.S. academic institutions: 1992–2012






EPO = European Patent Office.

SOURCE: The Patent Board™ special tabulations (2013) of Proprietary Patent database.



- Historical perspectives
- Learning from the case
- Policy making

Issue 1: Substitute to basic research?



"I'm an idea man."



LITERATURE ON 'ANTI-COMMONS'

Expansion of IPR is privatizing the scientific commons and limiting scientific progress

Heller and Eisenberg (1998); Argyres and Liebskind (1998); David (2000);
 Lessig (2002); Etzkowitz (1998); Krimsky (2003)

Murray and Stern (2007): "Do formal intellectual property rights hinder the free flow of scientific knowledge? An empirical test of the anti-commons hypothesis"


- Citation patterns of publications in pre-grant period and after grant
- 169 patent-paper pairs (Nature Biotechnology)
- Modest anti-commons effect: decline in citation rate by 10 to 20% (at grant)



Detection of patent-publication pairs Magerman et al., 2015, RP

Does involvement in patenting jeopardize one's academic footprint? An analysis of patent-paper pairs in biotechnology

Magerman, Van Looy, Debackere (2015, Research Policy)








Table 6: Differences in lifespan H-index between patenting authors and authors refraining from patenting activity (data sourced from Thomson Reuters Web of Science Core Collection)

Matching

H-Index measured for the overall period under observation

number of publications (+/- 10%)

	Treatment group	Control group	Difference	N	Significance level	Authors' H
Identical lifespan; identical initial H- index	15.45	12.01	3.44	48,791	0.000	VS Datanting Authors'
Identical lifespan; identical initial H- index; comparable highly cited paper during lifespan (+/- 10%)	15.86	8.6	7.26	6,603	0.000	Patenting Authors'
Identical lifespan; identical initial H- index; comparable highly cited paper in 1997 (+/- 10%)	15.57	9.58	5.984	5,828	0,000	Magerman et al., 2015
Identical lifespan; identical initial H-index; comparable highly cited paper 1997 (+/- 10%); comparable portfolio composition (normalized distance < 0,4)	17.20	10.59	6.61	834	0,000	
Identical lifespan; identical initial Hindex; comparable highly cited paper 1997 (+/- 10%); comparable portfolio composition (normalized distance < 0,3)	18.07	10.93	7.14	376	0,000	
Identical lifespan; identical initial Hindex; comparable highly cited paper 1997 (+/- 10%); comparable total number of publications (+/- 10%)	14.05	9.93	4.11	636	0,000	
Identical lifespan; identical initial H- index; comparable highly cited paper 1997 (+/- 10%); comparable portfolio composition (normalized distance < 0,4); comparable total number of publications (+/- 10%)	14.6	10.27	4.329	85	0,000	
Identical lifespan; identical initial H- index; comparable highly cited paper 1997 (+/- 10%); comparable portfolio composition (normalized distance < 0,3); comparable total	15.85	10.67	5.18	33	0,000	U

ULB



- Historical perspectives
- Learning from the two cases
- Policy making
- Issue 1: Substitute to basic research?

Issue 2: blocking innovation?



Would patents block further research?

As patents are rights to exclude, there are growing fears that they could impede basic research:

- US Court decision "Madey vs Duke"
- A few isolated cases, especially in the USA

Special case: the Onco Mouse in the USA

Murray, Aghion, Dewatripont, Kolev, and Stern (2009)

Droping patents on Mice: increase in the level of follow-on research and more diverse research paths...





Would patents block further research?

Surveys by Cohen et al. (2002 and 2005)

- 1% of US biomedical academic researchers: delay of more than a month, or project modified
- 8% reported modifying a project due to difficulties for accessing TANGIBLE inputs (data, tests, etc)
- => more problems are induced by scientific *competition between researchers*and promotion schemes than by patents (race for publications, proprietary databases)



- Historical perspectives
- Learning from the case
- Policy making
- Issue 1: Substitute to basic research?
- Issue 2: Blocking innovation?

Issue 3: Private or social value?

Government-funded research increasingly fuels innovation

Lee Fleming, UC Berkeley
Hillary Greene, University of Connecticut
Guan Cheng Li, UC Berkeley
Matt Marx, Boston University
Dennis Yao, Harvard

2019

This research funded by <u>SciSIP</u> Award #1536022.

Also thank you to Coleman Fung Institute for Engineering Leadership, University of Connecticut Law School, Questrom School of Business, and Harvard Business School.













Patentees increasingly depend upon federally supported research

Total granted U.S. patents by U.S. inventors (blue bars), and subtotal that rely on federal research (orange bars), and proportion of patents (black line = orange bars/blue bars) that rely on federally supported research.







Reliant patents also have a higher 'value'

More likely to be (highly) cited

More likely to be renewed

Contain more words new to the patent corpus



- Historical perspectives
- Learning from the case
- Policy making
- Issue 1: Substitute to basic research?
- Issue 2: Blocking innovation?
- Issue 3: private or social value?

Issue 4: People "management"?

Governance, emotions & skills



TTO typology

We theoretically identify four major TTO types

(a) Degree of discipline spec.	Discipline-integrated								Discipline- specialized		
(c) Level of autonomy granted	Dependent			Independent							
(d) Degree of exclusivity	Exclusive					Non-exclusive					
(b) Degree of task spec.	Fully integ.	Backw. integ.	Forw. integrat ed	Fully integ.	Backw. integ.	Forw. integ.	Fully integ.	Forw. integ.	IP spec.	Fully integr.	Forw. integr.
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
ТТО Туре	I. Classical TTO		II. Autonomous TTO			III. Discipline-integrated TTA			IV. Discipline- specialized TTA		

- Each TTO type has strengths and weaknesses (depends on university and environment)
- Performance measurement should take into account the typology

Schoen, van Pottelsberghe, Henkel, JoTT, 2014, Governance typology of universities' technology transfer processes




Creative tensions over TTO Officers?

Professor/Pr. Inv.:

\$ Return? No time! Star... influence

Researcher

No experience, But Boss/Her baby Anxiety for career



University

Reduce costs!
Research matters first!
Right of 1st refusal
Scyzophrenic deals

VCs/BAs

Urgent !!!
Licencing to expensive
Un. Innefficient
Right of 1st refusal

Incubators

Priority
Always TTO's fault

ULB



Challenging managerial decisions:

- Patent filing a poor indicator, research funding is a priority
- Governance of the POC (third parties involved?)
- Governance of the spin-off (researcher to manager? Who decides?)
- Separate IP (invention) issues from entrepreneurial issues (stock options)
- Right of first refusal (for venture funding)?
- Link promotion to patent filings... (correlates +) ?
- willingness to search/check novelty/F20 before research starts?
- + TTO, but organizational design matters (vision/integrated (R2B?)/specialized/skills/resources/shared...)
- Trust matters (scientific expertise, localized, transparency, fair practice,...)



references

- Guellec D. and B. van Pottelsberghe de la Potterie, 2007, The Economics of the European Patent System, <u>Oxford University Press</u>, Oxford, 250 p.
- Mathieu A., M. Meyer and B. van Pottelsberghe de la Potterie, 2008, Turning science into business: a case study of a major European research university,
 <u>Science and Public Policy</u>, forthcoming.
- van Pottelsberghe de la Potterie B., 2007, Hot Patent Issues, Chapter 7, in Guellec D. and B. van Pottelsberghe de la Potterie, The Economics of the European Patent System, *Oxford University Press*, Oxford, 250 p.
- Van Zeebroeck N., B. van Pottelsberghe and D. Guellec, Patents and academic research: a state of the art, 2008, *Journal of Intellectual Capital*, Vol. 9, N° 2, pp. 246-263.